Tysabri Progressive Multifocal Leukoencephalopathy Attorney: What Documentation Supports a Tysabri PML Claim?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Focused Risk Communication

The legacy of general health and science information has long served as a foundation for public understanding of medical treatments and their associated risks. Within this broad context, the dissemination of knowledge about therapeutic interventions has traditionally focused on benefits and common side effects, often framed for a general audience. As the field of pharmacovigilance has matured, the need to address specific, rare adverse events has become more pronounced. This shift is particularly evident in the transition from broad health education to focused discussions on medication exposure and its potential consequences. In the domain of mass production, where pharmaceuticals are manufactured and distributed at scale, the emphasis on population-level safety data naturally leads to scrutiny of individual patient outcomes. The bridge from general health context to occupational exposure concern is built upon the recognition that certain therapies, while beneficial for many, carry distinct risks that require careful documentation. This documentation becomes critical when considering the legal and medical implications of adverse events, especially in cases where exposure to a medication like Tysabri is linked to conditions such as progressive multifocal leukoencephalopathy. The focus thus pivots from general health information to the specific evidentiary requirements for assessing risk in exposed individuals.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus (JCV). The following narrative synthesizes evidence from FDA labeling and peer-reviewed literature to describe the clinical presentation, mechanistic links, and risk considerations relevant to patients and legal counsel. Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system that typically occurs in immunocompromised individuals. A retrospective national cohort study of 456 Italian PML patients observed between 1987 and 2024 found that 82.4% had a definite diagnosis and 17.6% had a clinico-radiological diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). The condition is caused by JC polyomavirus and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Tysabri-treated patients, PML presents with progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid.

Mechanism of Action and Risk Factors

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance in the central nervous system. The FDA-approved labeling states that Tysabri increases the risk of PML, an opportunistic viral infection of the brain caused by JCV that typically only occurs in immunocompromised patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). By blocking lymphocyte trafficking, Tysabri reduces the ability of the immune system to control JCV reactivation in the brain, allowing the virus to infect oligodendrocytes and cause demyelination. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling also notes that Tysabri should not be used in combination with immunosuppressants or inhibitors of TNF-alpha in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Regulatory Warnings and Documentation for Legal Evaluation

The adequacy of warnings regarding Tysabri and PML is a central consideration for affected patients and their legal representatives. The FDA requires a boxed warning that states Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also notes that risk factors include anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For attorneys representing patients who developed PML after Tysabri exposure, key considerations include the timeline between treatment initiation and symptom onset. The risk increases with longer treatment duration, particularly beyond two years. Documentation of anti-JCV antibody status, prior immunosuppressant use, and the duration of Tysabri therapy is critical for establishing the relationship between exposure and harm. The boxed warning explicitly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Medical records should be reviewed for evidence that the patient was informed of these risks and that monitoring protocols were followed.

Conclusion: Evidence Summary for Legal Counsel

In summary, the evidence demonstrates a clear mechanistic link between Tysabri and PML through impaired immune surveillance in the brain. The FDA has mandated strong warnings, including a boxed warning and a restricted distribution program, to mitigate this risk. Patients who develop PML after Tysabri exposure face a disease that usually leads to death or severe disability, and legal evaluation should focus on risk factor documentation, timing of symptoms, and adequacy of informed consent. References: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962) (https://pubmed.ncbi.nlm.nih.gov/40922664/)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What documentation is needed to support a Tysabri PML claim?

Key documentation includes medical records confirming Tysabri exposure, anti-JCV antibody test results, duration of Tysabri therapy, prior immunosuppressant use, brain MRI showing PML lesions, and CSF analysis positive for JCV DNA. Also important are records of informed consent and monitoring per the TOUCH program.

How does Tysabri increase the risk of PML?

Tysabri blocks lymphocyte migration into the brain, impairing immune surveillance. This allows JC virus to reactivate and infect oligodendrocytes, causing demyelination. The FDA boxed warning states Tysabri increases PML risk, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.